Teva raised AUSTEDO’s 2026 revenue guidance to a range of $2.45 billion to $2.6 billion, an increase of $50 million at the midpoint. Teva raised its full-year UZEDY forecast by $15 million at the midpoint to a range of $270 million to $290 million. Generics pressure and biosimilar expansionGlobal generics revenue fell 15% year over year, primarily because of a lower contribution from generic Revlimid. Excluding generic Revlimid, Francis said the generics business was stable, with global generics down 2% and U.S. generics up 1%. About Teva Pharmaceutical Industries (NYSE:TEVA)Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines.